0001209191-23-041393.txt : 20230705
0001209191-23-041393.hdr.sgml : 20230705
20230705210845
ACCESSION NUMBER: 0001209191-23-041393
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230703
FILED AS OF DATE: 20230705
DATE AS OF CHANGE: 20230705
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gauthier George
CENTRAL INDEX KEY: 0001857434
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39045
FILM NUMBER: 231071793
MAIL ADDRESS:
STREET 1: C/O IGM BIOSCIENCES, INC.
STREET 2: 325 E. MIDDLEFIELD ROAD
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IGM Biosciences, Inc.
CENTRAL INDEX KEY: 0001496323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770349194
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 325 E MIDDLEFIELD ROAD
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 650-965-7873
MAIL ADDRESS:
STREET 1: 325 E MIDDLEFIELD ROAD
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
FORMER COMPANY:
FORMER CONFORMED NAME: Palingen, Inc.
DATE OF NAME CHANGE: 20100712
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-07-03
0
0001496323
IGM Biosciences, Inc.
IGMS
0001857434
Gauthier George
C/O IGM BIOSCIENCES, INC.
325 E. MIDDLEFIELD ROAD
MOUNTAIN VIEW
CA
94043
0
1
0
0
Chief Commercial Officer
0
Common Stock
2023-07-03
4
S
0
936
9.4209
D
40017
D
The sale reported by the Reporting Person was effected pursuant to a Rule 10b5-1 trading plan, entered into on December 29, 2022, prior to the effectiveness of the revised requirements of Rule 10b5-1(c). In compliance with SEC guidance, the Reporting Person has not checked the box above but states that the Rule 10b5-1 trading plan is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
This transaction was executed in multiple trades at prices ranging from $9.22 to $9.54. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
/s/ Misbah Tahir, by power of attorney
2023-07-05